Crosslink Therapeutics
Boston, US · Founded 2021 · Delaware corporation · 1 known investors
Founders & leadership
RD
Ronald D. Seidel, IIINamed on SEC filing
Board
CG
Cameron GallagherBoard director
LT
RC
Rodolfo ChaparroBoard director
AK
Investors · 1
Reported raises · per SEC filings
Form D private placements$4.3M disclosed across 1 round · 2025
▶$4.3MraisedMay 2025 · 6 investors · PharmaceuticalsRule 506(b)
▶$4.3MraisedMay 2025 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ronald D. Seidel, IIIExecutive Officer, Director
- Cameron GallagherDirector
- Lou TartagliaDirector
- Rodolfo ChaparroDirector
- Andrew KingExecutive Officer
- Offering amount
- $8M
- Amount sold
- $4.3M
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- Who are Crosslink Therapeutics's investors?
- Crosslink Therapeutics's investors include Cure Ventures.
- How much funding has Crosslink Therapeutics raised?
- Crosslink Therapeutics has disclosed $4.3M raised across 1 round.
- Where is Crosslink Therapeutics headquartered?
- Crosslink Therapeutics is headquartered in Boston, US.